文献速递白血病浆细胞疾病

用于白血病和多发性骨髓瘤获批药物的关键临床试验是否代表了风险人群

Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk?
PubMed 文献 · J Clin Oncol · 2022-08-09

该研究评估了导致白血病和多发性骨髓瘤药物获批的关键临床试验在人口学和地理多样性上是否匹配受影响人群。共分析41项报告种族数据的试验(67.2%),纳入13731例患者,其中11209例(81.6%)为白人。黑人、美洲原住民和西班牙裔比例显著偏低,女性在急性髓系白血病中比例偏低,男性在多发性骨髓瘤和慢性髓系白血病中比例偏低。

要点

  • 41项(67.2%)报告种族的试验纳入13731例患者,11209例(81.6%)为白人。
  • 亚裔太平洋岛民和黑人在慢性髓系白血病中代表性最高,分别为147例(12.7%)和61例(5.3%)。
  • 女性在急性髓系白血病中比例偏低(44.7% vs 60.5%,P < .0001)。

核心结论

  • 与受影响人群相比,导致白血病和多发性骨髓瘤药物获批的关键临床试验存在显著的人口学和地理代表性不足与失衡,这些差异需要解决以使结果适用于所有相关人群。

研究设计与样本

  • 从美国食品药品监督管理局数据库识别导致药物获批的临床试验,从ClinicalTrials.gov和原始手稿收集人口学和地理数据,按种族、民族、性别和恶性肿瘤亚型以频率和比例(包括95% CI)进行标准描述性统计。

主要发现

  • 共41项(67.2%)试验报告种族数据,20项(48.8%)报告民族数据,共纳入13731例患者,其中11209例(81.6%)为白人。
  • 亚裔太平洋岛民和黑人在慢性髓系白血病中代表性最高,分别为147例(12.7%)和61例(5.3%),在慢性淋巴细胞白血病中最低,分别为55例(3%)和20例(1.1%)。
  • 黑人、美洲原住民和西班牙裔的比例显著偏低,反映其在试验中的代表性不足。
  • 女性在急性髓系白血病中代表性不足(44.7% vs 60.5%,P < .0001),男性在多发性骨髓瘤(55.3% vs 60.2%,P < .0001)和慢性髓系白血病(55.2% vs 62.9%,P < .0001)中代表性不足。
  • 试验的地理分布显示,除多发性骨髓瘤外,所有恶性肿瘤的区域和州参与度与死亡率相比不足。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There are significant disparities in care and outcomes for patients with leukemias and multiple myeloma (MM). To evaluate the extent to which clinical trials (CTs) match the demographic and geographic diversity of populations affected by leukemias and MM. METHODS: CTs leading to drug approval were identified from the US Food and Drug Administration databases. Demographic and geographic data were collected from ClinicalTrials.gov and primary manuscripts. Standard descriptive statistics were used to summarize the data in frequencies and proportions, including 95% CIs, by race, ethnicity, sex, and malignancy subtypes. RESULTS: A total of 41 (67.2%) trials leading to drug approval reported data on race and 20 (48.8%) on ethnicity. These trials included 13,731 patients, of whom 11,209 (81.6%) were White. Among minorities, Asian-Pacific Islanders and Blacks had the highest representation in chronic myeloid leukemia, 147 (12.7%) and 61 (5.3%), and lowest in chronic lymphocytic leukemia, 55 (3%) and 20 (1.1%), respectively. Proportions for Blacks, Native Americans, and Hispanics were significantly low, reflecting under-representation in trials compared with the proportion in the general population. Females were also under-represented in acute myeloid leukemia (44.7% v 60.5%, P < .0001), and males in MM (55.3% v 60.2%, P < .0001) and chronic myeloid leukemia (55.2% v 62.9%, P < .0001). The geographic distribution of trials showed inadequate regional and state participation compared with mortality for all malignancies except MM. CONCLUSION: There are significant demographic and geographic under-representation and imbalances in pivotal CTs leading to drug approvals for leukemias and MM compared with the population affected. These disparities need to be addressed to make results applicable to all relevant populations.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Casey M, Odhiambo L, Aggarwal N, et al. Are Pivotal Clinical Trials for Drugs Approved for Leukemias and Multiple Myeloma Representative of the Population at Risk? J Clin Oncol. 2022. PMID: 35944216. doi:10.1200/JCO.22.00504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。